<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Abstract Epstein–Barr virus (EBV) infects up to 95% of the" exact="adult" post="human population, with primary infection typically occurring during childhood"/>
 <result pre="infects up to 95% of the adult human population, with" exact="primary" post="infection typically occurring during childhood and usually asymptomatic. However,"/>
 <result pre="up to 95% of the adult human population, with primary" exact="infection" post="typically occurring during childhood and usually asymptomatic. However, EBV"/>
 <result pre="the adult human population, with primary infection typically occurring during" exact="childhood" post="and usually asymptomatic. However, EBV can cause infectious mononucleosis"/>
 <result pre="occurring during childhood and usually asymptomatic. However, EBV can cause" exact="infectious mononucleosis" post="in approximately 35–50% cases when infection occurs during adolescence"/>
 <result pre="during childhood and usually asymptomatic. However, EBV can cause infectious" exact="mononucleosis" post="in approximately 35–50% cases when infection occurs during adolescence"/>
 <result pre="EBV can cause infectious mononucleosis in approximately 35–50% cases when" exact="infection" post="occurs during adolescence and early adulthood. Epstein–Barr virus is"/>
 <result pre="Epstein–Barr virus is also associated with several B-cell malignancies including" exact="Burkitt lymphoma," post="Hodgkin lymphoma, and post-transplant lymphoproliferative disease. A number of"/>
 <result pre="is also associated with several B-cell malignancies including Burkitt lymphoma," exact="Hodgkin lymphoma," post="and post-transplant lymphoproliferative disease. A number of antiviral drugs"/>
 <result pre="several B-cell malignancies including Burkitt lymphoma, Hodgkin lymphoma, and post-transplant" exact="lymphoproliferative disease." post="A number of antiviral drugs have proven to be"/>
 <result pre="be effective inhibitors of EBV replication, yet have resulted in" exact="limited" post="success clinically, and none of them has been approved"/>
 <result pre="has been limited? The problem is illustrated by the commonest" exact="infection" post="caused by EBV in Western countries: infectious mononucleosis (IM)."/>
 <result pre="by the commonest infection caused by EBV in Western countries:" exact="infectious mononucleosis" post="(IM). First, its onset is insidious with nondescript sore"/>
 <result pre="the commonest infection caused by EBV in Western countries: infectious" exact="mononucleosis" post="(IM). First, its onset is insidious with nondescript sore"/>
 <result pre="actively replicating for some time and shed from the oropharyngeal" exact="epithelial" post="cells. Consequently, drugs given largely post-facto are too late."/>
 <result pre="epithelial cells. Consequently, drugs given largely post-facto are too late." exact="Infectious" post="mononucleosis is essentially an immunologic condition triggered by EBV"/>
 <result pre="cells. Consequently, drugs given largely post-facto are too late. Infectious" exact="mononucleosis" post="is essentially an immunologic condition triggered by EBV that"/>
 <result pre="immunologic condition triggered by EBV that is signaled by the" exact="atypical" post="T-cell response in the blood. It therefore can be"/>
 <result pre="with antiviral and immunosuppressive drugs might have an impact on" exact="infectious mononucleosis." post="However, in trials in which corticosteroid and antiviral drugs"/>
 <result pre="virus with essentially no toxicity [2] because it selectively inhibited" exact="viral" post="but not cellular replication. Its antiviral effective dose (ED50)"/>
 <result pre="the cellular polymerase alpha. Acyclovir triphosphate is incorporated into the" exact="viral" post="DNA where it forms a tight dead-end complex that"/>
 <result pre="mechanisms used by cells once every cell cycle, maintaining a" exact="stable" post="number through successive generations. It is not itself oncogenic,"/>
 <result pre="as the molecular basis of the latent state of EBV" exact="infection" post="[5]. No inhibitors of EBV latent infection have materialized"/>
 <result pre="state of EBV infection [5]. No inhibitors of EBV latent" exact="infection" post="have materialized over the decades. Accordingly, despite prolonged suppression"/>
 <result pre="have materialized over the decades. Accordingly, despite prolonged suppression of" exact="viral" post="replication, some latently infected cells will persist and will"/>
 <result pre="the population of the latent cells. At the same time," exact="non-toxic" post="antiviral drugs are indispensable for treatment, and potentially prophylaxis,"/>
 <result pre="antiviral drugs are indispensable for treatment, and potentially prophylaxis, of" exact="infection" post="in inborn and acquired immunodeficiency syndromes in which the"/>
 <result pre="for treatment, and potentially prophylaxis, of infection in inborn and" exact="acquired" post="immunodeficiency syndromes in which the latent genome has been"/>
 <result pre="treatment, and potentially prophylaxis, of infection in inborn and acquired" exact="immunodeficiency" post="syndromes in which the latent genome has been reactivated."/>
 <result pre="has been reactivated. Reactivation in immunosuppressed individuals results in abundant" exact="viral" post="replication that has the potential for genesis of B-cell"/>
 <result pre="is normally checked by efficient T-cell responses. 3. Acyclovir and" exact="Infectious" post="Mononucleosis Acyclovir is a nucleoside analog as are penciclovir,"/>
 <result pre="with brivudin (BVDU), they are approved for the therapy of" exact="herpes" post="simplex virus 1 (HSV-1) and varicella-zoster virus (VZV) associated"/>
 <result pre="Administration) or EMA (European Medicines Agency) for treatment of EBV" exact="infections" post="[6]. In addition to its subtle onset, IM has"/>
 <result pre="(4–6 weeks), which results in late diagnosis in contrast to" exact="infections" post="caused by HSV or VZV. Thus, the difficulty in"/>
 <result pre="EBV infection, except in immunodeficient states when there is active" exact="viral" post="replication. ACV does reduce EBV shedding in the oropharynx"/>
 <result pre="accompanied by discernible clinical benefit. Diagnostically, IM is characterized by" exact="atypical" post="T-cell lymphocytosis that results from the massive cell-mediated immune"/>
 <result pre="clinical symptoms or development of EBV-specific cellular immunity [1,7]. The" exact="hepatitis" post="associated with IM has been shown to be accompanied"/>
 <result pre="IM has been shown to be accompanied by a high" exact="viral" post="burden [8,9], and accordingly specific antivirals could possibly alleviate"/>
 <result pre="common EBV-related complication, which is in any case, almost always" exact="benign" post="and self-limiting. 4. Chronic Active EBV and Post-Transplant Lymphoproliferative"/>
 <result pre="is in any case, almost always benign and self-limiting. 4." exact="Chronic" post="Active EBV and Post-Transplant Lymphoproliferative Disease (PTLD) Chronic active"/>
 <result pre="benign and self-limiting. 4. Chronic Active EBV and Post-Transplant Lymphoproliferative" exact="Disease" post="(PTLD) Chronic active EBV infection is rare. It is"/>
 <result pre="self-limiting. 4. Chronic Active EBV and Post-Transplant Lymphoproliferative Disease (PTLD)" exact="Chronic" post="active EBV infection is rare. It is characterized by"/>
 <result pre="Active EBV and Post-Transplant Lymphoproliferative Disease (PTLD) Chronic active EBV" exact="infection" post="is rare. It is characterized by a high EBV"/>
 <result pre="high EBV DNA load (103–107 copies/mL), indicative of active lytic" exact="viral" post="replication [10]. It is unrelated to the fatigue experienced"/>
 <result pre="as interferon-α and interleukin-2) have been used for treatment of" exact="chronic" post="active EBV but with limited success. Post-transplant lymphoproliferative disease"/>
 <result pre="been used for treatment of chronic active EBV but with" exact="limited" post="success. Post-transplant lymphoproliferative disease is a potentially fatal complication"/>
 <result pre="treatment of chronic active EBV but with limited success. Post-transplant" exact="lymphoproliferative disease" post="is a potentially fatal complication following stem cell and"/>
 <result pre="of chronic active EBV but with limited success. Post-transplant lymphoproliferative" exact="disease" post="is a potentially fatal complication following stem cell and"/>
 <result pre="50% who then seroconvert experience PTLD [11,12,13]. Most cases of" exact="early onset" post="PTLD (occurring during the first year following transplantation) are"/>
 <result pre="IL-6’s secretion in lytically infected cells that may promote early" exact="lymphoproliferative disease" post="[15]. IL-6 plays a crucial role in the maintenance"/>
 <result pre="secretion in lytically infected cells that may promote early lymphoproliferative" exact="disease" post="[15]. IL-6 plays a crucial role in the maintenance"/>
 <result pre="from an EBV-positive donor, and therefore were at risk of" exact="primary" post="infection with EBV [11]. Over the first post-transplant year,"/>
 <result pre="an EBV-positive donor, and therefore were at risk of primary" exact="infection" post="with EBV [11]. Over the first post-transplant year, antiviral"/>
 <result pre="or GCV resulted in a significantly decreased incidence of EBV" exact="primary" post="infection: 9/20 (45%) in the prophylaxis group versus 8/8"/>
 <result pre="8/8 (100%) in the non-prophylaxis group. There was a significantly" exact="lower" post="EBV viral load depending on the type and intensity"/>
 <result pre="in the non-prophylaxis group. There was a significantly lower EBV" exact="viral" post="load depending on the type and intensity of the"/>
 <result pre="(given to prevent human cytomegalovirus (HCMV) disease) in 73 EBV-seronegative" exact="adult" post="kidney recipients on early and late PTLD onset was"/>
 <result pre="received no-prophylaxis. Epstein–Barr virus PCR monitoring revealed that prophylaxis delayed" exact="primary" post="infection at 100 days, but early PTLD incidence was"/>
 <result pre="no-prophylaxis. Epstein–Barr virus PCR monitoring revealed that prophylaxis delayed primary" exact="infection" post="at 100 days, but early PTLD incidence was not"/>
 <result pre="groups. However, regarding late events, EBV-related neoplasia incidence was significantly" exact="lower" post="in treated patients among whom no cases were observed"/>
 <result pre="of evidence, this study suggests that antiviral prophylaxis could prevent" exact="late onset" post="PTLD. 6. Omaciclovir The carbocyclic nucleoside analog H2G, (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine,"/>
 <result pre="has less selectivity as a substrate for thymidine kinase (TK)." exact="Resistance" post="to H2G has been mapped in the VZV TK"/>
 <result pre="terminator, although incorporation of its triphosphate form (H2G-TP) results in" exact="limited" post="chain elongation. Also, H2G-TP has a longer intracellular half-life"/>
 <result pre="with VALM (http://www.epiphanybio.com) include a randomized, placebo-controlled, double-blind trial for" exact="infectious mononucleosis" post="[ClinicalTrials.gov Trial: NCT00575185]. Subjects over the age of 15"/>
 <result pre="VALM (http://www.epiphanybio.com) include a randomized, placebo-controlled, double-blind trial for infectious" exact="mononucleosis" post="[ClinicalTrials.gov Trial: NCT00575185]. Subjects over the age of 15"/>
 <result pre="[ClinicalTrials.gov Trial: NCT00575185]. Subjects over the age of 15 with" exact="acute" post="IM were randomized to 21 days VALM 4 g/day"/>
 <result pre="physical exam/symptoms scores from each visit during the treatment period." exact="Severity of" post="illness improved more quickly in the VALM group, but"/>
 <result pre="of individuals who had at least a 2-log10 decrease in" exact="viral" post="load in the oral compartment was also significantly greater"/>
 <result pre="benefit and the in vivo antiviral effect of VALM in" exact="acute" post="IM. 8. Maribavir Maribavir (MBV) is an investigational oral"/>
 <result pre="Unlike nucleoside and nucleotide analogs, MBV does not target the" exact="viral" post="DNA polymerase. Its inhibitory effects are mainly produced through"/>
 <result pre="were distinct and conferred no cross-resistance [24,25], while there was" exact="partial" post="cross-resistance between GCV and cyclopropavir (CPV). However, later investigations"/>
 <result pre="activity against EBV through a unique dual effect, inhibition of" exact="viral" post="DNA replication and of virus transcription [6,26]. In contrast"/>
 <result pre="PK [28]. Considering that EBV BGLF4 has at least 20" exact="viral" post="targets, MBV may also affect downstream targets indirectly. 9."/>
 <result pre="(HPMPC), a nucleoside analogue, has been used for treatment of" exact="papillomatosis" post="in the hypopharynx and esophagus caused by human papillomavirus"/>
 <result pre="been used for treatment of papillomatosis in the hypopharynx and" exact="esophagus" post="caused by human papillomavirus (HPV) [29]. This drug is"/>
 <result pre="a mechanism that remains unclear. In experiments with EBV-positive nasopharyngeal" exact="carcinoma" post="(NPC) xenografts in nude mice, injection into the tumor"/>
 <result pre="nasopharyngeal carcinoma (NPC) xenografts in nude mice, injection into the" exact="tumor" post="tissue with cidofovir suppressed growth of the NPC tissue"/>
 <result pre="hydroxyurea and didox (3,4-dihydroxybenzohydroxamic acid) enhanced cidofovir-induced apoptosis in EBV-transformed" exact="epithelial" post="cells and in EBV-positive nasopharyngeal carcinoma xenografts [31]. 10."/>
 <result pre="cidofovir-induced apoptosis in EBV-transformed epithelial cells and in EBV-positive nasopharyngeal" exact="carcinoma" post="xenografts [31]. 10. Thymidine Derivatives L-dioxolane thymidine derivatives were"/>
 <result pre="of anti-EBV agents and their anti-herpesvirus activity was dependent on" exact="viral" post="TK. The HDVD analog (1-[(2S,4S-2-(hydroxymethyl)-1,3-dioxolan-4-yl]5-vinylpyrimidine-2,4(1H,3H)-dione) and its oral prodrug"/>
 <result pre="a mouse model of MHV-68 (a surrogate of EBV), reducing" exact="viral" post="replication in the lungs [32]. Two novel thiothymidine derivatives,"/>
 <result pre="Their antiviral activity proved to be dependent on phosphorylation by" exact="viral" post="TK and by cytosolic TK1. The efficacy of both"/>
 <result pre="to be dependent on phosphorylation by viral TK and by" exact="cytosolic" post="TK1. The efficacy of both thionucleosides in mice against"/>
 <result pre="TK1. The efficacy of both thionucleosides in mice against MHV-68" exact="acute" post="infection was mostly promising for KAH-39-149, which showed similar"/>
 <result pre="The efficacy of both thionucleosides in mice against MHV-68 acute" exact="infection" post="was mostly promising for KAH-39-149, which showed similar in"/>
 <result pre="have been largely ineffective. Past antiviral attempts have primarily targeted" exact="viral" post="replication and further research into new avenues of study,"/>
 <result pre="be necessary to develop effective therapy for EBV infections. EBV-triggered" exact="disease" post="can cause debilitating illness and death and antiviral therapy"/>
 <result pre="a major unmet medical need. Funding This research received no" exact="external" post="funding. Conflicts of Interest The authors declare no conflict"/>
 <result pre="conflict of interest. References References 1.TynellE.AureliusE.BrandellA.JulanderI.WoodM.YaoQ.Y.RickinsonA.AkerlundB.AnderssonJ.Acyclovir and prednisolone treatment of" exact="acute" post="infectious mononucleosis: A multicenter, double-blind, placebo-controlled studyJ. Infect. Dis.199617432433110.1093/infdis/174.2.3248699062"/>
 <result pre="of interest. References References 1.TynellE.AureliusE.BrandellA.JulanderI.WoodM.YaoQ.Y.RickinsonA.AkerlundB.AnderssonJ.Acyclovir and prednisolone treatment of acute" exact="infectious" post="mononucleosis: A multicenter, double-blind, placebo-controlled studyJ. Infect. Dis.199617432433110.1093/infdis/174.2.3248699062 2.PaganoJ.S.DattaA.K.Perspectives"/>
 <result pre="Dis.199617432433110.1093/infdis/174.2.3248699062 2.PaganoJ.S.DattaA.K.Perspectives on interactions of acyclovir with Epstein-Barr and other" exact="herpes" post="virusesAm. J. Med.198273182610.1016/0002-9343(82)90057-26285710 3.PaganoJ.S.SixbeyJ.W.LinJ.C.Acyclovir and Epstein-Barr virus infectionJ. Antimicrob."/>
 <result pre="efficiently inhibits oropharyngeal excretion of Epstein-Barr virus in patients with" exact="acute" post="infectious mononucleosisJ. Gen. Virol.198667 Pt 102267227210.1099/0022-1317-67-10-22673020162 8.DrebberU.KasperH.U.KrupaczJ.HaferkampK.KernM.A.SteffenH.M.QuasdorffM.Zur HausenA.OdenthalM.DienesH.P.The role"/>
 <result pre="inhibits oropharyngeal excretion of Epstein-Barr virus in patients with acute" exact="infectious" post="mononucleosisJ. Gen. Virol.198667 Pt 102267227210.1099/0022-1317-67-10-22673020162 8.DrebberU.KasperH.U.KrupaczJ.HaferkampK.KernM.A.SteffenH.M.QuasdorffM.Zur HausenA.OdenthalM.DienesH.P.The role of"/>
 <result pre="Virol.198667 Pt 102267227210.1099/0022-1317-67-10-22673020162 8.DrebberU.KasperH.U.KrupaczJ.HaferkampK.KernM.A.SteffenH.M.QuasdorffM.Zur HausenA.OdenthalM.DienesH.P.The role of Epstein-Barr virus in" exact="acute" post="and chronic hepatitisJ. Hepatol.20064487988510.1016/j.jhep.2006.02.00616554102 9.NegroF.The paradox of Epstein-Barr virus-associated"/>
 <result pre="102267227210.1099/0022-1317-67-10-22673020162 8.DrebberU.KasperH.U.KrupaczJ.HaferkampK.KernM.A.SteffenH.M.QuasdorffM.Zur HausenA.OdenthalM.DienesH.P.The role of Epstein-Barr virus in acute and" exact="chronic" post="hepatitisJ. Hepatol.20064487988510.1016/j.jhep.2006.02.00616554102 9.NegroF.The paradox of Epstein-Barr virus-associated hepatitisJ. Hepatol.20064483984110.1016/j.jhep.2006.03.00216554104"/>
 <result pre="10.SakamotoY.MariyaY.KuboK.Quantification of Epstein-Barr virus DNA is helpful for evaluation of" exact="chronic" post="active Epstein-Barr virus infectionTohoku J. Exp. Med.201222730731110.1620/tjem.227.30722850617 11.HockerB.BohmS.FickenscherH.KustersU.SchnitzlerP.PohlM.JohnU.KemperM.J.FehrenbachH.WiggerM.et al.(Val-)Ganciclovir"/>
 <result pre="infectionTohoku J. Exp. Med.201222730731110.1620/tjem.227.30722850617 11.HockerB.BohmS.FickenscherH.KustersU.SchnitzlerP.PohlM.JohnU.KemperM.J.FehrenbachH.WiggerM.et al.(Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus" exact="primary" post="infection in pediatric renal transplantationTranspl. Int.20122572373110.1111/j.1432-2277.2012.01485.x22533698 12.MaloufM.A.ChhajedP.N.HopkinsP.PlitM.TurnerJ.GlanvilleA.R.Anti-viral prophylaxis reduces"/>
 <result pre="J. Exp. Med.201222730731110.1620/tjem.227.30722850617 11.HockerB.BohmS.FickenscherH.KustersU.SchnitzlerP.PohlM.JohnU.KemperM.J.FehrenbachH.WiggerM.et al.(Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary" exact="infection" post="in pediatric renal transplantationTranspl. Int.20122572373110.1111/j.1432-2277.2012.01485.x22533698 12.MaloufM.A.ChhajedP.N.HopkinsP.PlitM.TurnerJ.GlanvilleA.R.Anti-viral prophylaxis reduces the"/>
 <result pre="pediatric renal transplantationTranspl. Int.20122572373110.1111/j.1432-2277.2012.01485.x22533698 12.MaloufM.A.ChhajedP.N.HopkinsP.PlitM.TurnerJ.GlanvilleA.R.Anti-viral prophylaxis reduces the incidence of" exact="lymphoproliferative disease" post="in lung transplant recipientsJ. Heart Lung Transplant.20022154755410.1016/S1053-2498(01)00407-711983544 13.HierroL.Diez-DoradoR.DiazC.De la"/>
 <result pre="renal transplantationTranspl. Int.20122572373110.1111/j.1432-2277.2012.01485.x22533698 12.MaloufM.A.ChhajedP.N.HopkinsP.PlitM.TurnerJ.GlanvilleA.R.Anti-viral prophylaxis reduces the incidence of lymphoproliferative" exact="disease" post="in lung transplant recipientsJ. Heart Lung Transplant.20022154755410.1016/S1053-2498(01)00407-711983544 13.HierroL.Diez-DoradoR.DiazC.De la"/>
 <result pre="reduces the incidence of lymphoproliferative disease in lung transplant recipientsJ." exact="Heart" post="Lung Transplant.20022154755410.1016/S1053-2498(01)00407-711983544 13.HierroL.Diez-DoradoR.DiazC.De la VegaA.FraucaE.CamarenaC.Munoz-BartoloG.Gonzalez de ZarateA.Lopez SantamariaM.JaraP.Efficacy and"/>
 <result pre="valganciclovir in liver-transplanted children infected with Epstein-Barr virusLiver Transpl.2008141185119310.1002/lt.2149818668670 14.GreenM.MichaelsM.G.Epstein-Barr" exact="virus infection" post="and posttransplant lymphoproliferative disorderAm. J. Transplant.201313Suppl. 3415410.1111/ajt.1200423347213 15.JonesR.J.SeamanW.T.FengW.H.BarlowE.DickersonS.DelecluseH.J.KenneyS.C.Roles of"/>
 <result pre="in liver-transplanted children infected with Epstein-Barr virusLiver Transpl.2008141185119310.1002/lt.2149818668670 14.GreenM.MichaelsM.G.Epstein-Barr virus" exact="infection" post="and posttransplant lymphoproliferative disorderAm. J. Transplant.201313Suppl. 3415410.1111/ajt.1200423347213 15.JonesR.J.SeamanW.T.FengW.H.BarlowE.DickersonS.DelecluseH.J.KenneyS.C.Roles of"/>
 <result pre="and posttransplant lymphoproliferative disorderAm. J. Transplant.201313Suppl. 3415410.1111/ajt.1200423347213 15.JonesR.J.SeamanW.T.FengW.H.BarlowE.DickersonS.DelecluseH.J.KenneyS.C.Roles of lytic" exact="viral infection" post="and IL-6 in early versus late passage lymphoblastoid cell"/>
 <result pre="posttransplant lymphoproliferative disorderAm. J. Transplant.201313Suppl. 3415410.1111/ajt.1200423347213 15.JonesR.J.SeamanW.T.FengW.H.BarlowE.DickersonS.DelecluseH.J.KenneyS.C.Roles of lytic viral" exact="infection" post="and IL-6 in early versus late passage lymphoblastoid cell"/>
 <result pre="5,6-dichloro-2-(isopropylamino)-1-beta- l-ribofuranosyl-1H-benzimidazoleJ. Virol.1999737271727710438815 21.PrichardM.N.Function of human cytomegalovirus UL97 kinase in" exact="viral infection" post="and its inhibition by maribavirRev. Med. Virol.20091921522910.1002/rmv.61519434630 22.ChouS.ErcolaniR.J.SahooM.K.LefterovaM.I.StrasfeldL.M.PinskyB.A.Improved detection"/>
 <result pre="l-ribofuranosyl-1H-benzimidazoleJ. Virol.1999737271727710438815 21.PrichardM.N.Function of human cytomegalovirus UL97 kinase in viral" exact="infection" post="and its inhibition by maribavirRev. Med. Virol.20091921522910.1002/rmv.61519434630 22.ChouS.ErcolaniR.J.SahooM.K.LefterovaM.I.StrasfeldL.M.PinskyB.A.Improved detection"/>
 <result pre="Med. Virol.20081823324610.1002/rmv.57418383425 26.WangF.Z.RoyD.GershburgE.WhitehurstC.B.DittmerD.P.PaganoJ.S.Maribavir inhibits epstein-barr virus transcription in addition to" exact="viral" post="DNA replicationJ. Virol.200983121081211710.1128/JVI.01575-0919759127 27.MurataT.IsomuraH.YamashitaY.ToyamaS.SatoY.NakayamaS.KudohA.IwahoriS.KandaT.TsurumiT.Efficient production of infectious viruses requires"/>
 <result pre="in addition to viral DNA replicationJ. Virol.200983121081211710.1128/JVI.01575-0919759127 27.MurataT.IsomuraH.YamashitaY.ToyamaS.SatoY.NakayamaS.KudohA.IwahoriS.KandaT.TsurumiT.Efficient production of" exact="infectious" post="viruses requires enzymatic activity of Epstein-Barr virus protein kinaseVirology2009389758110.1016/j.virol.2009.04.00719427010"/>
 <result pre="of HPV-associated lesionsVerh. K. Acad. Geneeskd. Belg.2001639312011436421 30.YoshizakiT.WakisakaN.KondoS.MuronoS.ShimizuY.NakashimaM.TsujiA.FurukawaM.Treatment of locally" exact="recurrent" post="Epstein-Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovirJ."/>
 <result pre="Acad. Geneeskd. Belg.2001639312011436421 30.YoshizakiT.WakisakaN.KondoS.MuronoS.ShimizuY.NakashimaM.TsujiA.FurukawaM.Treatment of locally recurrent Epstein-Barr virus-associated nasopharyngeal" exact="carcinoma" post="using the anti-viral agent cidofovirJ. Med. Virol.20088087988210.1002/jmv.2116518360900 31.WakisakaN.YoshizakiT.Raab-TraubN.PaganoJ.S.Ribonucleotide reductase"/>
 <result pre="Virol.20088087988210.1002/jmv.2116518360900 31.WakisakaN.YoshizakiT.Raab-TraubN.PaganoJ.S.Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal" exact="carcinoma" post="xenograftsInt. J. Cancer200511664064510.1002/ijc.2109615818619 32.CoenN.SinghU.VuyyuruV.Van den OordJ.J.BalzariniJ.DuraffourS.SnoeckR.ChengY.C.ChuC.K.AndreiG.Activity and mechanism of"/>
 <result pre="two novel 4′-thiothymidine derivatives, KAY-2-41 and KAH-39-149, are dependent on" exact="viral" post="and cellular thymidine kinasesAntimicrob. Agents Chemother.2014584328434010.1128/AAC.02825-1424820089"/>
</results>
